Active Pharmaceutical Ingredients (APIs) suna taka muhimmiyar rawa a cikin masana'antar harhada magunguna kuma sune tushen farko na kera duk magunguna.
Girman kasuwa na masana'antar harhada magunguna ta Japan ita ce ta biyu a Asiya.Tare da karuwar kudaden R&D na masana'antar harhada magunguna da wasu dalilai, ana sa ran kasuwar APIs ta Japan za ta yi girma a wani matsakaicin matsakaicin darajar 7% zuwa 8% nan da 2025. Daga cikinsu, kamfanonin harhada magunguna da suka taka rawar gani sun hada da. Sun Pharmaceutical, Teva, Novartis International AG, Piramal Enterprises, da Aurobindo.
Har ila yau, ci gaban masana'antar magunguna ta Japan yana fuskantar cikas na rashin isassun kayan masarufi masu zaman kansu.Kusan kashi 50 cikin 100 na abubuwan da ake shigo da su cikin gida na APIs ana amfani da su don samar da magunguna na yau da kullun, kuma manyan masu samar da kayayyaki na duniya sun fito ne daga ƙasashen Asiya da Turai kamar Indiya, China, Koriya ta Kudu, Italiya, Spain, Hungary da Jamus.Domin rage dogaro ga APIs da aka shigo da su, Japan tana mai da hankali kan gano APIs.
Sumitomo Pharmaceuticals, kamfani na farko a Japan don samar da magungunan sinadarai ta hanyar amfani da fasahar hada magunguna na zamani, yana shirin gina sabon APIs na ƙananan ƙwayoyin ƙwayoyin cuta da masana'anta na tsaka-tsaki a cikin Oita City, Oita Prefecture.Babban makasudin aikin shine haɓaka ƙarfin samar da API na kamfani don biyan buƙatun haɓakar APIs masu inganci da tsaka-tsaki.
An shirya sabon shuka a cikin Satumba 2024. Sashen haɓaka kwangila da masana'antu (CDMO) yana amfani da fasaha na musamman don samarwa da samar da ƙananan APIs na ƙwayoyin cuta da tsaka-tsaki don kamfanonin ƙira, da kuma gane tallace-tallace na kasuwanci na waje.Saboda tsananin buƙatar sabbin ayyukan haɓaka magunguna, kasuwar CDMO na magunguna ta duniya ta ci gaba da haɓaka ci gaba.An kiyasta cewa darajar kasuwancin duniya na yanzu na maganin CDMO ya kai kusan dalar Amurka biliyan 81, kwatankwacin yen tiriliyan 10.
Dogaro da kyakkyawan tsarin tabbatar da ingancinsa da fa'idodin sarrafa sarkar samar da kayayyaki na duniya, Sumitomo Pharmaceuticals a hankali ya haɓaka kasuwancin CDMO na tsawon shekaru kuma ya kafa babban matsayi a Japan.Tsirransa a Gifu da Okayama suna da ƙaramin ƙarfin samarwa.Ƙarfin samarwa na APIs da tsaka-tsaki da ake buƙata don magungunan ƙwayoyin cuta.Kamfanin kwangilar magunguna na Jafananci Bushu Corporation ya cimma yarjejeniyar haɗin gwiwa tare da Kamfanin Suzuken Pharmaceutical a cikin Afrilu 2021 don samar da sabon tallafin haɓaka samfuri ga ƙwararrun kamfanonin harhada magunguna da ke da niyyar shiga kasuwar Japan.Bushu yana fatan aiwatar da yarjejeniyar haɗin gwiwa don samar da APIs na cikin gida kai tsaye, ta hanyar haɗin gwiwar kamfanonin harhada magunguna guda biyu, don ba da sabis na gudanarwa na tsayawa ɗaya don buƙatar magunguna na musamman, gami da haɓaka shawarwarin masu ba da izini / masu muggan ƙwayoyi. shigo da, kimantawar kasuwa, samarwa da samarwa, ajiya da sufuri da aka ba da amana, kimanta haɓakawa da taimakon haƙuri da sauran ayyuka.
Bugu da kari, Bushu Pharmaceuticals na iya isar da magunguna cikin aminci ga marasa lafiya a duk tsawon aikin ta hanyar amfani da tsarin sa ido kan sarkar sanyi na musamman (Cubixx) wanda Suzuken Co., Ltd ya kirkira. Bugu da kari, Kamfanin Magunguna na Astellas na Japan ya bayyana cewa bisa ga bayanin. shirin fadada samarwa na uku, tushen API don samar da tsayayyen magungunan da aka kafa a Toyama, Japan a cikin Janairu 2020 za a yi amfani da shi don kera ainihin Astellas Prograf's tacrolimus hydrate API.
Tacrolimus magani ne wanda ke hanawa kuma yana kula da ƙin yarda da gabobin jiki a cikin manya da marasa lafiya na yara waɗanda suka karɓi hanta, koda, zuciya (da huhu sabon amincewar FDA a cikin 2021).
Lokacin aikawa: Juni-03-2019
